RET and breast carcinoma: There are only few in vitro studies on this compound showing a high selectivity for RET (IC50 of 8 nM) and an ability to inhibit RET signaling in breast cancer (MCF-7) and papillary thyroid carcinoma (TPC-1) cell lines at low concentrations [31,48].